AI Protein Structure Prediction Patents

AI protein structure prediction & design patents cover structure-prediction-model innovations; generative-protein-design innovations; protein-language-model innovations; and designed-protein, application, and method innovations — BUT the field's defining feature is that much of the core technology is OPEN-SOURCED/published, reshaping IP strategy. WHY AI PROTEIN STRUCTURE PREDICTION: predicting a protein's 3D STRUCTURE from its amino-acid sequence was a 50-year grand challenge — DeepMind's AlphaFold essentially SOLVED it, transforming biology (structures for nearly all known proteins); the frontier has expanded to predicting protein COMPLEXES/interactions and, crucially, generative protein DESIGN (creating new proteins, enzymes, and binders that don't exist in nature). MAJOR PROTEIN-AI HOLDERS/CONTRIBUTORS: DEEPMIND / ISOMORPHIC LABS (AlphaFold 2/3 — Isomorphic commercializes for drug discovery), BAKER LAB / INSTITUTE FOR PROTEIN DESIGN (RoseTTAFold, RFdiffusion generative design — Nobel Prize), GENERATE BIOMEDICINES, EVOLUTIONARYSCALE (ESM3 protein language model), CRADLE, CHAI DISCOVERY, NABLA BIO. CRITICAL IP NUANCE: AlphaFold2 (code + a database of millions of structures), ESM, and RoseTTAFold were OPEN-SOURCED/published — a massive boon to the field but meaning the core PREDICTION models are largely NOT patentable/are freely usable; so IP value shifts to APPLICATIONS, proprietary newer models/data (trade-secret), specific methods, and the DESIGNED PROTEINS themselves. Structure-prediction, generative design, language models, and applications/designed-proteins are the core domains — and generative design, proprietary models/data, designed-protein compositions, and §101-defensible methods are where defensible value lies.

Structure-prediction-model innovations; protein-language-model innovations; complex/interaction-prediction innovations; and §101 and open-source considerations represent core protein-AI patent domains — but because the leading models are PUBLISHED/OPEN and software-AI faces §101 scrutiny, patenting the prediction models themselves is limited (a key strategic reality). STRUCTURE-PREDICTION-MODEL PATENTS: deep-learning models mapping sequence → 3D structure (AlphaFold's Evoformer/attention architecture, MSA processing, end-to-end structure modules) — but AlphaFold2 was OPEN-SOURCED and the methods PUBLISHED, so the foundational prediction approach is largely freely usable (an FTO OPPORTUNITY, not a patenting opportunity for new entrants); novel/improved architectures may still be patentable. PROTEIN-LANGUAGE-MODEL PATENTS: models learning protein 'language' from sequences alone (ESM-style) to predict structure/function/design — many are open (ESM open-sourced); novel training/architectures could be patentable. COMPLEX / INTERACTION-PREDICTION PATENTS: predicting protein-protein, protein-LIGAND (drug binding), and protein-DNA/RNA complexes (AlphaFold3) — a higher-value, less-saturated frontier; specific methods may be patentable. §101 / OPEN-SOURCE CONSIDERATIONS: protein-prediction methods are software/algorithms facing ABSTRACT-IDEA (Alice) scrutiny, AND the leading models are open/published — so patenting the models is doubly hard; the strategic implication is to protect DOWNSTREAM value (designs, applications) rather than the prediction algorithm. Improved/proprietary models and interaction-prediction may be patentable, but the dominant strategic insight is that core prediction is OPEN — so defensible IP lives downstream (design/applications/data), not in the prediction model.

Generative-protein-design innovations; de-novo-binder/enzyme innovations; designed-protein composition innovations; and application and proprietary-data innovations represent additional protein-AI patent domains — and because the prediction models are open, the DEFENSIBLE, high-value IP is in protein DESIGN methods and (above all) the DESIGNED PROTEINS themselves. GENERATIVE-PROTEIN-DESIGN PATENTS: AI that GENERATES new proteins — diffusion models (RFdiffusion), generative models that design novel structures/scaffolds/binders to specification; generative design METHODS are more novel/patentable than prediction (and a fast-moving frontier) — though some are also open, specific design pipelines/methods are valuable IP. DE-NOVO-BINDER / ENZYME PATENTS: designing DE NOVO binders (proteins that bind a chosen target — for therapeutics/diagnostics), novel ENZYMES (for biomanufacturing/catalysis), and functional proteins; the design methods and the resulting molecules are high-value. DESIGNED-PROTEIN COMPOSITION PATENTS: the KEY value — the specific DESIGNED PROTEIN (a novel sequence/binder/enzyme/therapeutic) is directly patentable as COMPOSITION-OF-MATTER (Generate, Baker spinouts, Isomorphic's drug candidates) — this is where protein-AI creates the most defensible, valuable IP (the product, not the algorithm). APPLICATION / PROPRIETARY-DATA PATENTS: applying protein AI to drug discovery (binders/therapeutics), enzyme/industrial design, and antibody design; and proprietary MODELS/DATA (experimental structure/design datasets, lab-in-the-loop) often kept as TRADE SECRET (the real moat when models are commoditized). Generative design methods, de novo binders/enzymes, and (above all) the specific DESIGNED PROTEINS as composition-of-matter are the highest-value IP because — with prediction models open — the defensible value is in novel design methods and the patentable molecules they create.

Protein-AI startup IP strategy must reckon with the OPEN-SOURCE reality (AlphaFold/ESM/RoseTTAFold are freely available — you can USE them but can't patent them, and so can everyone else), the §101 abstract-idea problem for AI methods, the proprietary-data/model moat (often trade-secret), DeepMind/Isomorphic/Baker IP, the design-vs-prediction value shift, the application focus (drugs/enzymes), and a landscape where generative design, designed proteins, applications, and proprietary data are the durable assets; understand that prediction is commoditized/open, so the durable IP is in novel generative-design methods, the DESIGNED PROTEINS (composition-of-matter), proprietary data/models, and application-specific pipelines, and that the designed molecules, data moat, and application value matter as much as (or more than) patents on methods; identify whitespace in generative design, designed-protein compositions, and interaction prediction. PROTEIN-AI STARTUP IP STRATEGY: PREDICTION IS OPEN/COMMODITIZED — DESIGN METHODS, DESIGNED PROTEINS, APPLICATIONS, AND DATA ARE THE IP: AlphaFold/ESM/RoseTTAFold are open (use freely, can't patent), so build IP in generative DESIGN, the DESIGNED MOLECULES, applications, and proprietary data — not the prediction model; THE DESIGNED PROTEIN ITSELF IS THE HIGHEST-VALUE IP (COMPOSITION-OF-MATTER): a novel designed binder/enzyme/therapeutic is directly patentable as a product — this is where protein-AI creates defensible, valuable IP (the molecule, not the algorithm); GENERATIVE DESIGN METHODS ARE MORE NOVEL/PATENTABLE THAN PREDICTION: diffusion/generative design pipelines (RFdiffusion-style) and de novo binder/enzyme design methods are a fast-moving, more-patentable frontier (though watch open-source overlap); PROPRIETARY DATA/MODELS ARE THE REAL MOAT (OFTEN TRADE-SECRET): experimental structure/design/lab-in-the-loop datasets and proprietary newer models drive advantage — weigh trade secret vs patent (and patents on AI methods face §101); §101 LIMITS PATENTING AI METHODS — FOCUS ON CONCRETE/COMPOSITION CLAIMS: abstract 'predict structure with a neural network' is weak — claim designed compositions, concrete technical methods, or specific applications; INTERACTION/COMPLEX PREDICTION IS A LESS-SATURATED FRONTIER: protein-ligand/protein-protein prediction (drug binding) is higher-value and less crowded than monomer prediction; APPLICATION FOCUS (DRUGS/ENZYMES) IS WHERE VALUE CONCENTRATES: protein-AI's payoff is designed drugs/enzymes — the molecules and their uses are the assets; FTO IS EASY ON PREDICTION (IT'S OPEN) BUT WATCH DESIGN-METHOD IP: open prediction = freedom to operate, but design methods/molecules have IP; WHEN TO PATENT (OR KEEP SECRET): NOVEL DESIGN METHOD OR DESIGNED MOLECULE WITH MEASURED RESULTS: patent designed proteins (sequence/binder/function) and novel design methods once validated (binding affinity/function/developability/success rate); keep proprietary data/models as trade secret — the designed molecule and its validated function are the critical protein-AI IP; KEY FTO CHECKLIST: AlphaFold 2/3 (OPEN/published — freely usable, not patentable); ESM protein language model (open); RoseTTAFold (open); RFdiffusion generative design (Baker, partly open); Isomorphic Labs drug-discovery application; Generate/EvolutionaryScale/Cradle/Chai; structure-prediction model/Evoformer/MSA (open, §101); protein-language model; complex/interaction (protein-ligand/protein-protein) prediction; generative/diffusion protein design/de novo binder/enzyme; DESIGNED PROTEIN composition-of-matter (the key IP); proprietary structure/design data + lab-in-the-loop (trade-secret); §101 abstract-idea; application drug/enzyme/antibody design.